S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023

Avidity Biosciences Stock Price, News & Analysis (NASDAQ:RNA)

$7.54
-0.51 (-6.34%)
(As of 12/8/2023 ET)
Compare
Today's Range
$7.51
$8.10
50-Day Range
$4.87
$8.10
52-Week Range
$4.82
$25.74
Volume
1.06 million shs
Average Volume
2.07 million shs
Market Capitalization
$558.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.17

Avidity Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
406.2% Upside
$38.17 Price Target
Short Interest
Bearish
14.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.66) to ($3.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

782nd out of 942 stocks

Pharmaceutical Preparations Industry

375th out of 448 stocks


RNA stock logo

About Avidity Biosciences Stock (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock Price History

RNA Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Avidity Biosciences: FDA Grants Orphan Drug Designation To AOC 1044
RNA - Avidity Biosciences, Inc.
Where Avidity Biosciences Stands With Analysts
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
186
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.17
High Stock Price Target
$71.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+406.2%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-173,990,000.00
Net Margins
-1,995.34%
Pretax Margin
-1,995.34%

Debt

Sales & Book Value

Annual Sales
$10.14 million
Book Value
$8.29 per share

Miscellaneous

Free Float
72,619,000
Market Cap
$558.72 million
Optionable
Not Optionable
Beta
0.49
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 54)
    Ph.D., Co-Founder & Chairman
    Comp: $67.5k
  • Ms. Sarah Boyce (Age 51)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Michael F. MacLean (Age 57)
    Chief Financial & Chief Business Officer
    Comp: $701.64k
  • Dr. W. Michael Flanagan Ph.D. (Age 61)
    Chief Scientific & Technical Officer
    Comp: $678.74k
  • Ms. Teresa McCarthy (Age 59)
    Chief Human Resources Officer
    Comp: $665.14k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
  • Dr. Frank P. McCormick Ph.D. (Age 73)
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Geoffrey M. Grande C.F.A.
    VP of Investor Relation & Corporate Communication
  • Dr. John W. Wallen III (Age 65)
    VP of Intellectual Property, General Counsel & Secretary
  • Ms. Kathleen Gallagher
    Senior VP of Global Program & Head DM1














RNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price target for 2024?

6 brokers have issued 12-month target prices for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $71.00. On average, they expect the company's share price to reach $38.17 in the next year. This suggests a possible upside of 406.2% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2023?

Avidity Biosciences' stock was trading at $22.19 at the beginning of the year. Since then, RNA stock has decreased by 66.0% and is now trading at $7.54.
View the best growth stocks for 2023 here
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.05. The biotechnology company earned $2.82 million during the quarter, compared to the consensus estimate of $2.09 million. Avidity Biosciences had a negative net margin of 1,995.34% and a negative trailing twelve-month return on equity of 36.55%.

What ETFs hold Avidity Biosciences' stock?

ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Morningstar US Small Growth (MSGR) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Adage Capital Partners GP L.L.C. (1.75%), Alethea Capital Management LLC (1.15%), Northern Trust Corp (0.86%), Charles Schwab Investment Management Inc. (0.70%) and Rafferty Asset Management LLC (0.53%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce.
View institutional ownership trends
.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RNA) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -